Abstract: The present invention relates to a solid oral dosage form comprising a therapeutically effective amount of aliskiren, or a pharmaceutically acceptable salt thereof, and wherein the active ingredient is present in an amount of more than 46% by weight based on the total weight of the oral dosage form.
Type:
Grant
Filed:
June 15, 2005
Date of Patent:
August 30, 2011
Assignee:
Novartis AG
Inventors:
Petra Gisela Rigassi-Dietrich, Martin Schmid
Abstract: The present invention provides methods for increasing arterial compliance. The methods generally involve administering to an individual in need thereof an effective amount of relaxin. The present invention further provides methods of increasing arterial compliance in individuals who have Type 1 or Type 2 diabetes. The present invention further provides methods of increasing arterial compliance in perimenopausal, menopausal, and post-menopausal women. The present invention further provides methods of increasing arterial compliance in individuals who have or who are at risk of developing age-associated arterial stiffness.
Type:
Grant
Filed:
March 18, 2005
Date of Patent:
February 1, 2011
Assignee:
University of Pittsburgh- Of The Commonwealth System of Higher Education
Abstract: The invention related to a novel process, novel process steps and novel intermediates useful in the synthesis of pharmaceutically active compounds, especially renin inhibitors, such as Aliskiren. Inter alia, the invention relates to a process for the manufacture of a compound of the formula II, or a salt thereof, and a compound of formula VI or a salt thereof, wherein R3 and R4 as well as Act are as defined in the specification, and processes of manufacturing these. Additionally transformation of compounds (VI) with metallo organic compounds (VII) give rise to the new compounds (VIII) which are direct precursors for the preparation of Aliskiren.
Type:
Grant
Filed:
October 16, 2006
Date of Patent:
August 10, 2010
Assignee:
Novartis AG
Inventors:
Gottfried Sedelmeier, Dominique Grimler, Murat Acemoglu
Abstract: The present invention provides a method for improving the bioavailability of a renin inhibitor, preferably, of a ?-amino-?-hydroxy-?-aryl-alkanoic acid derivative, which method comprises co-administering to a mammal, especially a human, in need of such treatment, a combination of a renin inhibitor, or a pharmaceutically acceptable salt thereof, and an efflux protein inhibitor.
Type:
Grant
Filed:
August 2, 2005
Date of Patent:
May 4, 2010
Assignee:
Novartis AG
Inventors:
Gian P. Camenisch, Gerhard Gross, Isabel Ottinger, Daniel Wasmuth